SCHEMBL520795

SCHEMBL520795

CSc1ncc2ccc(-c3cccc(S(=O)(=O)NC(C)(C)C)c3)n2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 10/20 0.58
PTK2 Q05397 4/20 0.53
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KCNH2 Q12809 2/20 0.36
INSR P06213 1/20 0.35
ALK Q9UM73 1/20 0.35
ALDH1A1 P00352 1/20 0.34
PARG Q86W56 1/20 0.34
PIK3CD O00329 3/20 0.34
PIK3CG P48736 3/20 0.34
PIK3CA P42336 2/20 0.34
PIK3CB P42338 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL520134 0.85 JAK2 (0.60) JAK2PTK2KDM4EMEN1NPC1
SCHEMBL521447 0.85 JAK2 (0.41) JAK2PTK2KDM4EMAPTHPGD
SCHEMBL520771 0.84 JAK2 (0.59) JAK2PTK2KDM4EMEN1NPC1
SCHEMBL522170 0.83 JAK2 (0.41) JAK2PTK2KCNH2INSRALK
SCHEMBL519748 0.82 JAK2 (0.56) JAK2PTK2KDM4EMEN1NPC1
Nitrous Acid SCHEMBL521356 0.79 JAK2 (0.38) JAK2PTK2KDM4EMAPTHPGD
SCHEMBL520031 0.79 JAK2 (0.69) JAK2PTK2INSRALKJAK1
SCHEMBL520071 0.79 JAK2 (0.74) JAK2PTK2INSRALKJAK1
SCHEMBL521256 0.78 JAK2 (0.43) JAK2PTK2KCNH2INSRALK
SCHEMBL521920 0.78 JAK2 (0.51) JAK2PTK2KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2376491-B1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON INC (US) 2015-03-04 EP disclosed
US-8471005-B2 Pyrrolotriazines as ALK and JAK2 inhibitors CEPHALON, INC. (US) 2013-06-25 US disclosed
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2012-02-02 US disclosed
EP-2376491-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS Cephalon, Inc. (US) 2011-10-19 EP disclosed
WO-2010071885-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS CEPHALON, INC. (US) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028919-A1 PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS JAK2, ALK, ABL1 JAK2 1/4885PTK2 592/4885KDM4E 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.